NEW YORK (GenomeWeb) – As liquid biopsy genetic tests have rocketed into clinical practice over the last handful of years, clinical researchers, test developers, and others have begun to pay increasing attention to a relative lack of tools to ensure assays are validated and performed according to common, or at least equivalent standards.
The lack of adequate circulating tumour DNA reference materials for developing and measuring safe, accurate, and reproducible assays continues to be a challenge for clinical labs.
Clinical labs are adopting next-generation sequencing technology at ever increasing rates.
Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples.
New Orleans, LA – June 4, 2017 – Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical assay that can detect the Zika virus from semen samples.
NEW YORK (GenomeWeb) – SeraCare Life Sciences has announced a collaboration with the US National Institute of Standards and Technology (NIST) to develop circulating tumor DNA (ctDNA) reference standard materials for diagnostics.
SeraCare Life Sciences, Milford, Mass, has launched the AccuPlex Zika reference material to fast-track the development and validation of polymerase chain reaction (PCR)-based Zika virus assays.
SeraCare and Toma Bio have developed a solid tumor gene analysis kit. — GenomeWeb
inShare SeraCare Launches Circulating Tumor DNA Reference Materials for NGS and Digital PCR-based Oncology Assays
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
NEW YORK (GenomeWeb) – SeraCare Life Sciences today announced a licensing agreement with the University of California, San Francisco for the use of its trisomy 21, 18, and 13 trophoblast cell line materials to develop reference materials for non-invasive prenatal testing of chromosomal abnormalities.
The new precision medicine business unit of SeraCare Life Sciences, Milford, Mass, has launched its first product, the Seraseq solid tumor mutation mix I.
The market leaders in the global legionella testing market are involved in continuous efforts for the development of innovative methodologies of testing which would increase the efficiency and accuracy of test results while providing the smooth processing of larger samples simultaneously.